-
Reports: Watson plans to buy Actavis
NEW YORK — Generic drug maker Watson Pharmaceuticals is looking to acquire Actavis, according to published reports.
News media reported Wednesday that U.S.-based Watson was close to taking over Switzerland-based Actavis for $6.6 to $7.3 billion. Actavis, also a major manufacturer of generic drugs, was formerly based in Iceland and moved its headquarters to Switzerland last year.
-
Teva to list shares on New York Stock Exchange
JERUSALEM — Israel-based Teva Pharmaceutical Industries is switching stock exchanges, the company said.
The world's largest generic drug manufacturer — and increasingly a player in branded and specialty drugs — announced Wednesday that it would transfer the listing of its shares from the Nasdaq to the New York Stock Exchange, with plans to start trading on the NYSE on May 30 under its current ticker symbol, "TEVA."